Matthew Sincock, MD
Infectious Disease · Wilmington, NCNPI 1851550255
Payments from drug & device makers
Across 746 payments — averaging $367.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$186K
- GSK$80K
- Gilead$2K
- AbbVie$1K
- Merck$942
- Melinta Therapeutics, LLC$655
- plus $4K from 25 others
Across 10 payments — averaging $334.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$3K
What the payments were for
- Consulting fees$17,71018%
- Speaking & faculty fees$60,37562%
- Travel & lodging$5,8916%
- Food & beverage$13,16914%
- Education$2270%
- Gifts$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 230 | $186,373 |
| GSK | 49 | $79,564 |
| Gilead | 96 | $1,589 |
| AbbVie(2 entities) | 66 | $1,121 |
| Merck | 57 | $942 |
| Melinta Therapeutics, LLC | 31 | $655 |
| Insmed, Inc. | 37 | $584 |
| Novo Nordisk | 31 | $519 |
| Astellas Pharma US Inc | 12 | $325 |
| Paratek Pharmaceuticals, Inc. | 16 | $298 |
| Tetraphase Pharmaceuticals, Inc. | 19 | $276 |
| Johnson & Johnson | 12 | $233 |
| Pfizer | 11 | $232 |
| Shionogi Inc | 11 | $227 |
| Grifols USA, LLC | 9 | $199 |
| Amgen | 11 | $184 |
| Lilly USA, LLC | 10 | $167 |
| Theratechnologies Inc. | 7 | $147 |
| Cumberland Pharmaceuticals, Inc. | 8 | $132 |
| Janssen Products, LP | 1 | $99 |
| Dynavax Technologies Corporation | 6 | $91 |
| Seqirus USA Inc | 5 | $90 |
| UCB, Inc. | 1 | $63 |
| La Jolla Pharmaceutical Company | 3 | $53 |
| Modernatx, Inc. | 1 | $25 |
| AstraZeneca | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Abbott | 1 | $18 |
| Angiodynamics, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$274,307 in reported general payments places this provider in the 90th percentile of 250 infectious disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 92 | $358,383 |
| DovatoDolutegravir Sodium/Lamivudine | 120 | $350,149 |
| TivicayDolutegravir Sodium | 93 | $235,844 |
| DescovyEmtricitabine/Tenofov Alafenam | 91 | $202,151 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 27 | $128,239 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 34 | $124,883 |
| CabenuvaCabotegravir/Rilpivirine | 13 | $86,544 |
| JulucaDolutegravir/Rilpivirine | 13 | $43,706 |
| Vancomycin Hcl | 50 | $6,793 |
| Darunavir | 23 | $4,690 |
| Daptomycin | 13 | $2,804 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 35 | $2,255 |
| Ritonavir | 24 | $2,111 |
| CeftriaxoneCeftriaxone Sodium | 49 | $1,829 |
| Cefadroxil | 78 | $1,760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Tivicay, Cabenuva, Juluca | $186,373 | $716,243239 claims |
| GileadBiktarvy, Descovy | $1,589 | $560,534183 claims |
| Janssen Products, LPSymtuza | $99 | $128,23927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 infectious disease providers in North Carolina.
Other infectious disease in Wilmington
- John SandersWilmington$2.4M
- Paul KamitsukaWilmington$13K
- Gina BertholdWilmington$10K
- John SandersWinston Salem$5.2M
- Cristina GasparettoDurham$3.2M
- Paul CookGreenville$2.9M
- Susanna NaggieDurham$2.7M
- Mitchell HorwitzDurham$2M
- Cornelius van DamGreensboro$2M
- Frederick CruickshankHuntersville$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.